10-Q: Catheter Precision Reports Q3 2024 Results, Highlights Ongoing Restructuring and Financial Challenges

Catheter Precision's Q3 2024 report reveals a net loss of $4.12 million, ongoing financial challenges, and strategic shifts following a merger, while also highlighting new product sales and a recent public offering.

Summary

• Catheter Precision reported a net loss of $4.12 million for the third quarter of 2024, compared to a net loss of $1.93 million in the same period last year.
• The company's revenue decreased to $96 thousand in Q3 2024 from $133 thousand in Q3 2023.
• For the nine months ended September 30, 2024, the net loss was $11.0 million, compared to a net loss of $69.9 million for the same period in 2023.
• The company's revenue for the first nine months of 2024 was $271 thousand, down from $314 thousand in the same period of 2023.
• Operating expenses totaled $2.9 million for the quarter and $8.4 million for the nine-month period.
• A significant portion of the prior year's loss was due to a $60.9 million impairment of goodwill related to the merger with Old Catheter.
• The company completed a public offering in September 2024, raising approximately $2.6 million in net proceeds.
• The company also amended short-term promissory notes with related parties, extending the maturity date to January 31, 2026, and increasing the interest rate to 12% per annum.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within 12 months from the date of the report.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a net loss, decreased revenue, and a going concern warning. While there are some positive developments, such as the public offering and new product sales, the overall sentiment is negative due to the company's precarious financial situation.

Positives

• The company successfully completed a public offering in September 2024, raising $2.6 million in net proceeds.
• The company has begun to rejuvenate its sales force, hiring ten sales people and three clinical support staff, along with a new Chief Commercial Officer.
• The company has received notification of the issuance of its first LockeT patent in China and completed a Middle East distribution agreement for LockeT.
• The company has made progress in remediating previously identified material weaknesses in internal control over financial reporting.
• The company has reduced the manufacturing cost of VIVO Positioning Patches by approximately 40%.

Negatives

• The company reported a net loss of $4.12 million for Q3 2024 and $11.0 million for the first nine months of 2024.
• Revenue decreased to $96 thousand in Q3 2024 from $133 thousand in Q3 2023.
• The company's management has expressed substantial doubt about its ability to continue as a going concern.
• The company has incurred recurring net losses from operations and negative cash flows from operating activities since inception.
• The company has an accumulated deficit of approximately $287 million as of September 30, 2024.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funding.
• The company may not be able to secure financing in a timely manner or on favorable terms.
• The company has a history of losses and may never achieve profitability.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's revenues may depend on customers receiving adequate reimbursement from private insurers and government-sponsored healthcare programs.
• The company may be unable to compete successfully with companies in its highly competitive industry.
• The company's future operating results depend on its ability to obtain components in sufficient quantities on commercially reasonable terms.
• The company's products may be subject to additional recalls, revocations, or suspensions after receiving regulatory approval.
• The company is subject to pervasive and continuing regulation by the FDA and other regulatory agencies.

Future Outlook

Management expects operating losses and negative cash flows to continue for the foreseeable future as the company invests in its commercial capabilities. The company's ability to continue as a going concern is dependent on raising additional funding.

Management Comments

• Management has expressed substantial doubt about the company's ability to continue as a going concern within 12 months from the date of the report.
• Management will continue to monitor its operating costs and seek to reduce its current liabilities.
• Management plans to raise additional capital through public or private equity or debt financings to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the unaudited condensed consolidated financial statements.

Industry Context

The company operates in the competitive medical device industry, specifically in the field of cardiac electrophysiology. The company's products, VIVO and LockeT, are aimed at addressing specific needs in this market. The company's financial challenges and restructuring efforts reflect the difficulties faced by smaller companies in this sector.

Comparison to Industry Standards

• The company's revenue of $96 thousand in Q3 2024 is significantly lower than that of established medical device companies, such as Medtronic or Abbott, which report billions in quarterly revenue.
• The company's net loss of $4.12 million in Q3 2024 is also indicative of the financial challenges faced by early-stage medical device companies, which often require significant investment in R&D and commercialization before achieving profitability.
• The company's reliance on external funding and its going concern warning are not uncommon for companies in this sector, particularly those that are pre-revenue or in the early stages of commercialization.
• The company's focus on innovative technologies, such as the VIVO System and LockeT, aligns with industry trends towards minimally invasive and advanced medical solutions.
• The company's recent public offering and warrant inducement offer are common strategies used by smaller companies to raise capital and manage their financial obligations.

Management Changes

Corporate Governance

Legal Proceedings

• As of September 30, 2024, the Company had no outstanding litigation.
• The company has an open sales and use tax audit with the California Department of Tax and Fee Administration covering the period from October 1, 2020 through March 31, 2023.

Related Party Transactions

• The company entered into short-term promissory notes with related parties totaling $1.5 million, which were later amended to extend the maturity date and increase the interest rate.
• David A. Jenkins and his affiliates received royalty rights equal to approximately 12% of the net sales of LockeT.
• David A. Jenkins and his affiliates received shares of Series X Convertible Preferred Stock in the merger.
• Mr. Jenkins' daughter received options to purchase shares of the company's common stock upon the closing of the merger.
• Margrit Thomassen received options to purchase shares of the company's common stock upon the closing of the merger and in January 2024.
• The Jenkins Family Charitable Institute invested approximately $500,000 in the company's public offering.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new equity securities.
• Employees may be affected by potential cost-cutting measures and restructuring efforts.
• Customers may be impacted by the company's ability to continue operations and provide ongoing support for its products.
• Suppliers may be affected by the company's financial challenges and potential changes in its operations.
• Creditors may be at risk due to the company's going concern warning and potential inability to repay debts.

Next Steps

• The company plans to raise additional capital through public or private equity or debt financings.
• The company will continue to monitor its operating costs and seek to reduce its current liabilities.
• The company will continue to implement its remediation plan for internal control weaknesses.
• The company expects CE Mark approval for LockeT in March 2025, at which time initial international shipments to distributors will begin.

Key Dates

Keywords

Catheter Precision, VIVO System, LockeT, cardiac electrophysiology, medical devices, financial results, public offering, going concern, internal control, warrant inducement